Latest Medtech News
Renata Medical has closed a $25 million Series D funding round to accelerate the global rollout and pipeline development of its paediatric stent technology. The round was led by private equity firm Archimed, with existing investors also participating. The California-based company's flagship product, Minima, is a balloon-expandable growth stent purpose-built for infants and young children with pulmonary artery stenosis or coarctation of the aorta - two forms of congenital heart defect (CHD) that, left untreated, can progress to heart failure and death.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
The fresh capital arrives on the back of real commercial and clinical momentum. Minima received FDA pre-market approval in August 2024, backed by strong data from the GROWTH pivotal trial: 97.6% of the 42 enrolled patients saw effective relief from stenosis, and all patients remained free of additional surgery at six months post-implant. CEO Dustin Armer said uptake has outpaced expectations since the 2024 launch, framing Archimed's backing as validation of the company's broader mission to transform CHD care. The new funds will support international commercialisation, expansion of Renata's paediatric-specific device pipeline, and continued evidence generation as adoption grows.
What sets Minima apart technically is its design logic: delivered via a small needle through the groin or neck, the stent can be crimped down to under 2mm, addressing one of paediatric interventional cardiology's toughest problems, safely accessing the tiny vessels of very young patients. The device will also be able to expand as the child grows. Archimed managing partner André-Michel Ballester, formerly CEO of LivaNova, pointed to the core unmet need driving the investment thesis: children with CHD have long been treated with adult-sized devices that can't grow with them, forcing repeat interventions.
Paediatric cardiology has historically been an underserved corner of device innovation, largely because small patient populations make the economics of dedicated R&D unattractive compared to adult cardiovascular markets. A $25m raise led by a PE firm rather than a strategic acquirer signals growing confidence that "growth-capable" paediatric devices can be a viable standalone category, not just a niche add-on. If Minima's international expansion goes well, it could set a commercial precedent that draws more capital into paediatric-specific device design, an area where the clinical need has long outpaced investment.
